SCM
SABS icon

Stonepine Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Stonepine Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
73,271
+23,271
+47% +$86.6K 0.16% 71
2026
Q1 		$192K Buy
+50,000
New +$199K 0.08% 72

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stonepine Capital Management's SABS Position: Q2 2026 in Review

Stonepine Capital Management increased its SAB Biotherapeutics (SABS) stake by 47% in Q2 2026, buying an estimated $86.6K and bringing the position to 73,271 shares worth $286K. The position accounts for 0.16% of the portfolio, ranked #71.

Stonepine Capital Management first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Stonepine Capital Management held 73,271 shares of SAB Biotherapeutics worth $286K as of Q2 2026.
  • Stonepine Capital Management bought 23,271 SAB Biotherapeutics shares in Q2 2026, an estimated $86.6K.
  • SAB Biotherapeutics made up 0.16% of Stonepine Capital Management's portfolio in Q2 2026, its #71 holding.
  • Stonepine Capital Management first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.